The Wall Street Journal Names Acceleron to “The Next Big Thing” List of Top 50 Start-Ups in the United States

September 27, 2012

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that it was recognized by the Wall Street Journal as one of the top 50 private venture-backed companies in the United States.  This is the second time that Acceleron was named to the list.

“Being recognized by the Wall Street Journal as one of the top 50 venture-backed companies in the U.S. is an honor and a great acknowledgement of our incredible employees, Board and partners, as well as the breakthrough science that serves as the foundation of our novel pipeline of products,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron. “Acceleron has recently made tremendous progress in advancing our pipeline of clinical-stage biologics and will deliver results from numerous Phase 2 clinical trials in 2013.  The next 12 months will be a transformative period in the evolution of the company.”    

Acceleron was selected for “The Next Big Thing – The Top 50 Venture-Backed Companies” based on criteria including fundraising success, recent growth in the company's value and the track record of its founders and board members. The editorial staff of Dow Jones VentureWire also reviewed and ranked the start-ups based on their knowledge of the companies' products, competition and financial performance. There were 5,900 companies considered for the ranking.    


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.